Company Announcements

Block Listing Six Monthly Return

Source: RNS
RNS Number : 2271L
Alliance Pharma PLC
29 December 2022


For immediate release

29 December 2022




("Alliance" or the "Company")


Block Listing Six Monthly Return



Name of applicant:


Names of schemes:

a)     The Alliance Pharma plc Approved Share Option Plan 2005

b)    The Alliance Pharma plc Share Option Plan 2006

c)     The Alliance Pharma plc Company Share Option Plan 2015

d)    The Alliance Pharma plc Long-Term Incentive Plan 2019

Period of return:


28 June 2022


28 December 2022

Number of securities originally admitted at date of admission:

25,000,000 ordinary shares of 1p each

28 June 2017

Balance of unallotted securities under schemes from previous return:

a)     161,946

b)    2,551,168

c)     9,654,020

d)    1,500,000

Plus:  The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):

a)     Nil

b)    Nil

c)     Nil

d)    Nil

Less:  Number of securities issued/allotted under schemes during period:

a)  12,309

b) 0

c)  81,398

d) 158,884


Equals:  Balance under schemes not yet issued/allotted at end of period:

e)     149,637

f)     2,551,168

g)    9,572,622

h)    1,341,116


Name of contact:

Chris Chrysanthou, Company Secretary

Telephone number of contact:

Tel. +44 (0)1249 705166





For further information:


Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168





+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff




Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith


Corporate Broking: James Black




Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams


Corporate Broking: Patrick Robb




About Alliance


Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, Alliance employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.